Big announcement

1. NIO's Q3 revenue rose 46.6% year on year, and car delivery volume reached a record high

$NIO-SW (09866.HK)$Q3 revenue was 19.07 billion yuan, falling short of market expectations of 19.37 billion yuan, up 46.6% year-on-year from the same period last year; net loss of 4,557 billion yuan, net loss of 4.111 billion yuan for the same period last year; and automobile deliveries in the third quarter reached 55,000 vehicles, the highest in history.

2. Pharmaceutical Biotech: The current stock price does not reflect value, and plans to buy back up to 10% of the company's shares for no more than 600 million US dollars

$WUXI BIO (02269.HK)$An announcement was issued. According to the repurchase authorization, the company was allowed to repurchase up to about 425 million shares from the Stock Exchange, accounting for 10% of the total number of shares issued on the day of the Annual General Meeting of Shareholders. The board of directors announced that on December 5, 2023, it has decided to use repurchase authorizations to repurchase shares on the open market from time to time at a total price of no more than 600 million US dollars. The company believes that the current trading price of shares does not reflect its intrinsic value or the company's actual business prospects, and the proposed share repurchase also reflects the company's confidence in its own business development prospects.

3. Taikoo Corporation plans to repurchase ordinary A shares and B shares for up to HK$6 billion

$SWIRE PACIFIC A (00019.HK)$and$SWIRE PACIFIC B (00087.HK)$In a joint announcement, the company's board of directors announced that it has approved plans to repurchase the company's common A shares and B shares through the open market. The maximum amount of shares to be repurchased is HK$6 billion. The plan will be funded from the company's available capital and cash reserves.

4. Greentown China's total contract sales amount for the first 11 months was about 256.4 billion yuan

$GREENTOWN CHINA (03900.HK)$According to the announcement, in November 2023, Greentown Group's sales amount was about RMB 20.4 billion, and the average sales price was about RMB 25,986 per square meter. From January to November 2023, Greentown Group obtained a contract sales area of about 5.98 million square meters, with a contract sales amount of approximately RMB 168.8 billion; of this, the equity amount attributable to Greentown Group was approximately RMB 111.5 billion.

Important matters

$EVERGRANDE (03333.HK)$Received a notice from the court about the recovery of Jinbi Property

$MNSO (09896.HK)$: I don't know any reason for recent fluctuations in stock prices or trading volume. Management plans to buy a number of shares on the open market within the next month

$MICROPORT (00853.HK)$: Plans to issue US$220 million 5.75% convertible bonds due 2028

$MING YUAN CLOUD (00909.HK)$I don't know any reason why the stock price fluctuates, and the order contract amount and repayment situation remain stable

$SENSETIME-W (00020.HK)$Further response to the short selling report

Operational data

$GAC GROUP (02238.HK)$: November car sales were 227,700 units, up 19.35% year on year

$GWMOTOR (02333.HK)$: The total sales volume in November was 122,849 units, up 40.3% year on year

$GREENTOWN CHINA (03900.HK)$The total contract sales amount for the first 11 months was about 256.4 billion yuan

$TRULY INT'L (00732.HK)$: The cumulative net consolidated turnover for the first 11 months was HK$14.014 billion

$MMG (01208.HK)$Ore reserves (metal content) as of June 30: cobalt increased 7%

$RONSHINECHINA (03301.HK)$Total contract sales for the first 11 months were about 15.3 billion yuan

$CONCORD NE (00182.HK)$Total equity power generation in November reached 716.14 GWh, up 23.34% year on year

Pharmaceutical Innovation

$SIRNAOMICS-B (02257.HK)$Announced the successful completion of the first phase I clinical trial for anticoagulant therapy based on the galnacrNAi therapy drug STP122g

$SINO BIOPHARM (01177.HK)$: TQA3038 “siRNA” phase I clinical trial completed administration of the first batch of subjects

$BIOCYTOGEN-B (02315.HK)$Whole-human antibody mouse RenMab? Key technology has been granted a US patent

$ASCLETIS-B (01672.HK)$: Initiate phase III clinical trial of ASC40 (denifastat) for acne

Repurchase cancellation

$SWIRE PACIFIC A (00019.HK)$: The Board of Directors has approved a share repurchase plan with a maximum amount of HK$6 billion

$TENCENT (00700.HK)$On December 5, 1.29 million shares were repurchased at a cost of HK$401 million

$HSBC HOLDINGS (00005.HK)$Repurchase of 3 million shares at a cost of HK$180 million on December 4

$AIA (01299.HK)$On December 5, 2,082 million shares were repurchased at a cost of HK$135 million

$XIAOMI-W (01810.HK)$Repurchase of 3.2 million shares at a cost of HK$47.07 million on December 5

$SINOPEC CORP (00386.HK)$On December 5, 10.31 million shares were repurchased at a cost of HK$404.78 million

$ESR (01821.HK)$Repurchase of 4 million shares at a cost of HK$38.2 million on December 5

$KUAISHOU-W (01024.HK)$On December 5, 700,000 shares were repurchased at a cost of HK$37.51 million

$CONCH CEMENT (00914.HK)$On December 5, it spent 2,025,000 yuan to repurchase 891,000 A-shares

$WANT WANT CHINA (00151.HK)$On December 5, 4 million shares were repurchased at a cost of HK$18.347,400

$COSCO SHIP HOLD (01919.HK)$On December 5, 2,343 million shares were repurchased at a cost of HK$16.7.03 million

$CHOW TAI FOOK (01929.HK)$On December 5, 1.4 million shares were repurchased at a cost of HK$15.41 million

$KINGSOFT (03888.HK)$On December 5, 615,000 shares were repurchased at a cost of HK$14.989 million

$BEKE-W (02423.HK)$On December 4, 386,600 shares were repurchased at a cost of 2 million US dollars

$YUM CHINA (09987.HK)$On December 4, 47,600 shares were repurchased at a cost of 2 million US dollars

$SKYWORTH GROUP (00751.HK)$Repurchase of 4 million shares at a cost of HK$11.784,400 on December 5

$HAIER SMARTHOME (06690.HK)$On December 5, it spent 9.49 million yuan to buy back 450,000 A-shares

$POP MART (09992.HK)$On December 5, 400,000 shares were repurchased at a cost of HK$8.3796 million

$HK TECH VENTURE (01137.HK)$On December 5, it spent HK$760.1 million to repurchase 3,084 million shares

$CONCORD NE (00182.HK)$On December 5, 9.7 million shares were repurchased at a cost of HK$6.42 million

$LIVZON PHARMA (01513.HK)$116.14,500 shares have been cancelled and A shares have been repurchased

edit/ruby